After a post-doctorate at the Lille Pasteur Institute, Olivier Barbier joined the Faculty of Pharmacy of Laval University and the CHU de Québec Research Center (endocrinology and nephrology axis) where he currently serves as full professor and independent scientist. With the invaluable assistance of his research professionals Mélanie Verreault and Jocelyn Trottier, Dr. Barbier has developed the laboratory of molecular pharmacology of the CHU de Québec Research Center. His research program aims at deciphering the bile acid signalling pathways in order to take advantage of their therapeutic potential in clinic. Research progresses of the last decades have revealed that these acids are not just cholesterol metabolites involved in fatty acid digestion, but play also a major role in controlling numerous biological functions such as glycaemia, inflammation and cell proliferation. Actually, the discovery of bile acid sensors (nuclear and membrane receptors) evidenced the role for these molecules as endo-, para- and intracrine hormones. In particular, these works lead to the approval by the FDA (2016) and Health Canada (2017) of the first synthetic bile acid (Ocaliva® or obeticholic acid, OCA) for the treatment of primary biliary cholangitis. In such an exciting context, researches of Barbier’s lab are focussing on 2 main subjects: auto-immune hepatobiliary diseases and prostate cancer.

Auto-immune hepatobiliary diseases (PBC et PSC)

Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are two rare diseases characterized by a reduction of bile flow and an accumulation of toxic bile acids in hepatic cells. This accumulation leads to chronic inflammation and to the destruction of liver cells. Dr. Barbier’s works aims at identifying new pharmaco-nutritional approaches (drug+nutrition treatment) providing a tight control of bile acid detoxification and, by so allowing a delay in diseases progression.

Prostate cancer

Prostate cancer mortality still represents 10% of Canadian death by cancer in 2017. The androgen receptor (AR) plays a critical role in the cancer progression, as well as in the development resistance to chemical castration, the first-line therapy for metastatic cancers. Members of the lab have observed that obeticholic acid (OCA) causes a near-complete inhibition of AR expression and activity in prostate cancer cell models. Dr. Barbier’s team currently works at developing this major discovery in order to bring it to patient’s bedside.

Excellence of Dr. Barbier’s work has been acknowledged by the reception of various prestigious awards (Association of Faculties of Pharmacy of Canada, Heart and Stroke Foundation – Québec, Pfizer Cardiovascular…), and by the publication of numerous peer-reviewed papers. He acts as a member of editorial board such as Drug Metabolism Review, PLoS One, The Canadian Journal of Gastroenterology and Hepatology. Besides his professor-researcher’s activities, Dr. Barbier also occupies important functions with institutional (University Council, Committee of Students Affairs of Laval University), provincial (Club de Recherche Clinique du Québec), national (Intern reviewer for the Canadian Institute of Health Research) and international authorities (Committee director of the Cholestatic and Biliary Disorders Special Interest Group, American Association for the Study of Liver Diseases).

CHUL
2705, boulevard Laurier
R-4701.7
Québec, Québec
Canada G1V 4G2

113 entries « 1 of 12 »

Morin-Bernier J, de Toro-Martín J, Barbe V, San-Cristobal R, Lemieux S, Rudkowska I, Couture P, Barbier O, Vohl MC

Revisiting multi-omics-based predictors of the plasma triglyceride response to an omega-3 fatty acid supplementation

Journal Article

Front Nutr, 11 , 2024.

Abstract | Links:

Morin-Bernier J, de Toro-Martín J, Barbe V, San-Cristobal R, Lemieux S, Rudkowska I, Couture P, Barbier O, Vohl MC

Corrigendum: Revisiting multi-omics-based predictors of the plasma triglyceride response to an omega-3 fatty acid supplementation

Journal Article

Front Nutr, 11 , 2024.

Abstract | Links:

Morissette A, de Wouters d'Oplinter A, Andre DM, Lavoie M, Marcotte B, Varin TV, Trottier J, Pilon G, Pelletier M, Cani PD, Barbier O, Houde VP, Marette A

Rebaudioside D decreases adiposity and hepatic lipid accumulation in a mouse model of obesity

Journal Article

Sci Rep, 14 (1), 2024.

Abstract | Links:

Desjardins C, Leblay L, Bélanger A, Filiatrault M, Barbier O, Guénette L, Leclerc J, Lefebvre J, Zongo A, Drouin-Chartier JP

Relationship Between Diet Quality and Glucose-Lowering Medication Intensity Among Adults With Type 2 Diabetes: Results From the CARTaGENE Cohort

Journal Article

CJC Open, 6 (1), 2024.

Abstract | Links:

Bélanger A, Desjardins C, Leblay L, Filiatrault M, Barbier O, Gangloff A, Leclerc J, Lefebvre J, Zongo A, Drouin-Chartier JP

Relationship Between Diet Quality and Statin Use Among Adults With Metabolic Syndrome From the CARTaGENE Cohort

Journal Article

CJC Open, 6 (1), 2024.

Abstract | Links:

Daniel N, Le Barz M, Mitchell PL, Varin TV, Julien IB, Farabos D, Pilon G, Gauthier J, Garofalo C, Kang JX, Trottier J, Barbier O, Roy D, Chassaing B, Levy E, Raymond F, Lamaziere A, Flamand N, Silvestri C, Jobin C, Di Marzo V, Marette A

Comparing Transgenic Production to Supplementation of ω-3 PUFA Reveals Distinct But Overlapping Mechanisms Underlying Protection Against Metabolic and Hepatic Disorders

Journal Article

Function (Oxf), 4 (2), 2023.

Abstract | Links:

Desjardins C, Cyrenne-Dussault M, Barbier O, Bélanger A, Gangloff A, Guénette L, Leclerc J, Lefebvre J, Zongo A, Drouin-Chartier JP

Are Lipid-Lowering and Antihypertensive Medications Used as Complements to Heart-Healthy Diets? A Scoping Review

Journal Article

Adv Nutr, 14 (4), 2023.

Abstract | Links:

Mahdavi A, Trottier J, Barbier O, Lebel M, Rudkowska I

Dairy Intake Modifies the Level of the Bile Acid Precursor and Its Correlation with Serum Proteins Associated with Cholesterol Clearance in Subjects with Hyperinsulinemia

Journal Article

Nutrients, 15 (22), 2023.

Abstract | Links:

Lebrun A, Fortin H, Fontaine N, Fillion D, Barbier O, Boudreau D

Pushing the Limits of Surface-Enhanced Raman Spectroscopy (SERS) with Deep Learning: Identification of Multiple Species with Closely Related Molecular Structures

Journal Article

Appl Spectrosc, 76 (5), 2022.

Abstract | Links:

Mennillo E, Yang X, Weber AA, Maruo Y, Verreault M, Barbier O, Chen S, Tukey RH

Intestinal UDP-Glucuronosyltransferase 1A1 and Protection against Irinotecan-Induced Toxicity in a Novel UDP-Glucuronosyltransferase 1A1 Tissue-Specific Humanized Mouse Model

Journal Article

Drug Metab Dispos, 50 (1), 2022.

Abstract | Links:

113 entries « 1 of 12 »
Signaler des ajouts ou des modifications

Active projects

  • Aminosteroid derivatives as a new class of cholesterol homeostasis disruptors for selective treatment of pancreatic cancer: Mechanistic and translational studies, from 2022-10-01 to 2027-09-30
  • Caractérisation de la relation entre les habitudes nutritionnelles et la prise en charge de la Cholangite Biliaire Primitive dans une cohorte de patients du Québec., from 2022-07-01 to 2024-06-30
  • Effet de contrôle glycémique sur la progression de la stéatose hépatique au sein du REGISTRE-NASH du CHU de Québec-Université Laval, from 2024-01-23 to 2024-12-31
  • Elucidating the differential contribution of sulfonation and glucuronidation in controlling nuclear receptor activity, from 2021-04-01 to 2026-03-31
  • Impact of the gut microbiome on the cardioprotective potential of diet in heterozygous familial hypercholesterolemia, from 2024-01-01 to 2026-12-31
  • Infrastructure de développement de nanomédecines pour le traitement des maladies du foie cholestatiques et autoimmunes, from 2023-05-01 to 2024-08-27
  • Interactions between Nordic environment and Chronobiotics: Impact on cardiometabolic and neurometabolic health, from 2020-11-01 to 2024-12-31
  • L'empreinte métabolomique plasmatique des produits laitiers: un reflet de leur consommation et une fenêtre sur leurs effets cardiométaboliques, from 2023-01-01 to 2025-09-03
  • Nanomatériaux pour cibler le microbiote intestinal et altérer le métabolisme des acides biliaires, from 2023-04-01 to 2026-03-31
  • The UGT to GUS equilibrium as novel target for the treatment of cholestatic autoimmune liver diseases, from 2021-04-01 to 2026-03-31

Recently finished projects

  • Acides biliaires et maladies inflammatoires chroniques de l’intestin : et si la solution était dans l’assiette?, from 2022-03-03 to 2023-03-02
  • Development of siRNA-based nanomedicines for the treatment of cholestatic autoimmune liver diseases, from 2022-09-21 to 2023-03-31
  • Dual anti-inflammatory and glucoregulatory actions of a small molecule analogue of the omega-3-derived pro-resolving protectin DX (PDX) for the treatment of obesity and insulin resistance, from 2022-04-01 to 2024-03-31
  • Identifying the biological basis of GWAS hits for plasma triglyceride response to an omega-3 fatty acid supplementation, from 2020-04-01 to 2024-03-31
  • Pharmaco-nutraceutics: the key to open the therapeutic window of anti-cholestatic drugs, from 2022-02-01 to 2023-01-31
  • Sympathetic Control of the Biliary System in NAFLD, from 2021-01-01 to 2022-12-31
Data provided by the Université Laval research projects registery